MRNA

Moderna Stock Is Soaring. Is It Too Late to Buy?

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More

Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%.

MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?